Elizabeth Bilotti

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

John C. Byrd, Richard R. Furman, Steven Coutré et al. · Blood · 2015 · 653 citations · Full text

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

Meletios Α. Dimopoulos, Judith Trotman, Alessandra Tedeschi et al. · The Lancet Oncology · 2016 · 231 citations

Open-label Substudy, Immunology, Clinical Trials +4

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

Paul G. Richardson, David S. Siegel, Rachid Baz et al. · Blood · 2012 · 161 citations · Full text

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Steven Coutré, Richard R. Furman, Ian W. Flinn et al. · Clinical Cancer Research · 2017 · 61 citations · Full text

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

Paul G. Richardson, William Bensinger, Carol Ann Huff et al. · British Journal of Haematology · 2018 · 36 citations · Full text